Jefferies Downgrades Quest Diagnostics to Hold, Announces $135 Price Target
Jefferies analyst Brian Tanquilut downgrades Quest Diagnostics (NYSE:DGX) from Buy to Hold and announces $135 price target.
Where Quest Diagnostics Stands With Analysts
Within the last quarter, Quest Diagnostics (NYSE:DGX) has observed the following analyst ratings:
Quest Diagnostics Launches COVID-19 Rapid Antigen Test Through QuestDirect
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of an at-home COVID-19 rapid antigen test service for consumer purchase, available through QuestDirect™, the company's consumer-initiated testing platform.
Quest Diagnostics Stock Falls As FY22 EPS Outlook Lags Consensus
Quest Diagnostics Inc (NYSE:DGX) expects Q4 sales of $2.74 billion, a decrease of 9% Y/Y, beating the consensus of $2.54…
Watching COVID Testing Plays Following Report US Insurers Have Said They Will Cover Up To 8 Home COVID Tests/Month
-Bloombering citing Associated Press